Skip to main content
Top
Published in: The journal of nutrition, health & aging 8/2018

01-10-2018

Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures

Authors: Gülistan Bahat, O. Yilmaz, C. Kiliç, M. M. Oren, M. A. Karan

Published in: The journal of nutrition, health & aging | Issue 8/2018

Login to get access

Abstract

Objective

To assess the reliability and validity of Turkish version of SARC-F in regard to screening with current definitions of sarcopenia, muscle mass and functional measures.

Design

Cross-sectional study.

Participants

Community-dwelling older adults aged >=65 years admitting to a geriatric outpatient clinic.

Measurements

Muscle mass (bioimpedance analysis), handgrip strength, usual gait speed, chair sit-to-stand test, functional reach test, short physical performance battery, SARC-F questionnaire, FRAIL questionnaire Sarcopenia was evaluated with 4 current different definitions: European Working Group on Sarcopenia in Older People’s (EWGSOP); Foundation for the National Institutes of Health (FNIH), International Working Group on Sarcopenia (IWGS) and Society on Sarcopenia, Cachexia and Wasting Disorders (SCWD).

Results

After cross-cultural adaptation, 207 subjects were analysed in the clinical validation study. Mean age was 74.6±6.7 years, 67.6% were women. Against EWGSOP, FNIH, IWGS and SCWD definitions of sarcopenia, sensitivity of SARC-F were %25, 31.6%, 50% and 40%; specificity were 81.4%, 82.4%, 81.8% and 81.7%, respectively. Positive predictive values were between 5.1-15.4% and negative predictive values were 92.3-98.2%. Against parameters of low muscle mass, sensitivity were about 20% and specificity were about 81%. Against parameters of function; for low hand grip strength, sensitivity of SARC-F were 33.7% (for Turkish cut-off); 50% (for FNIH cut-off); specificity were 93.7% (for Turkish cut-off) and 85.8% (for FNIH cut-off). Against low UGS, poor performance in chair sit to stand test, functional reach test, SPPB and presence of positive frailty screening sensitivity were 58.3%, 39.2%, 59.1%, 55.2% and 52.1% while specificity were 97.3%, 97.8%, 88.1%, 99.3% and 91.2%, respectively.

Conclusion

The psychometric performance of Turkish SARC-F was similar to the original SARC-F. It revealed low sensitivity but high specificity with all sarcopenia definitions. Sensitivity and specificity were higher for muscle function tests reflecting its inquiry and input on functional measures. Our findings suggest that SARC-F is an excellent test to exclude muscle function impairment and sarcopenia. SARC-F is relatively a good screening test for functional measures.
Appendix
Available only for authorised users
Literature
1.
go back to reference Tan LF, Lim ZY, Choe R, et al. Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with health care burden. J Am Med Dir Assoc 2017;24:583–587.CrossRef Tan LF, Lim ZY, Choe R, et al. Screening for frailty and sarcopenia among older persons in medical outpatient clinics and its associations with health care burden. J Am Med Dir Assoc 2017;24:583–587.CrossRef
3.
go back to reference Bahat G, Yilmaz O, Oren M, et al. Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. Eur Geriatr Med 2018;9:23–28.CrossRef Bahat G, Yilmaz O, Oren M, et al. Cross-cultural adaptation and validation of the SARC-F to assess sarcopenia: methodological report from European Union Geriatric Medicine Society Sarcopenia Special Interest Group. Eur Geriatr Med 2018;9:23–28.CrossRef
4.
go back to reference Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14:531–532.CrossRefPubMed Malmstrom TK, Morley JE. SARC-F: a simple questionnaire to rapidly diagnose sarcopenia. J Am Med Dir Assoc 2013;14:531–532.CrossRefPubMed
5.
go back to reference Parra-Rodriguez L, Szlejf C, Garci´a-Gonza´lez AI, et al. Cross-cultural adaptation and validation of the Spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults. J Am Med Dir Assoc 2016;17:1142–1146CrossRefPubMed Parra-Rodriguez L, Szlejf C, Garci´a-Gonza´lez AI, et al. Cross-cultural adaptation and validation of the Spanish-language version of the SARC-F to assess sarcopenia in Mexican community-dwelling older adults. J Am Med Dir Assoc 2016;17:1142–1146CrossRefPubMed
6.
go back to reference Ida S, Murata K, Nakadachi D, et al. Development of a Japanese version of the SARC-F for diabetic patients: an examination of reliability and validity. Aging Clin Exp Res 2017;29:935–942.CrossRefPubMed Ida S, Murata K, Nakadachi D, et al. Development of a Japanese version of the SARC-F for diabetic patients: an examination of reliability and validity. Aging Clin Exp Res 2017;29:935–942.CrossRefPubMed
7.
go back to reference Barbosa-Silva TG, Menezes AMB, Bielemann, RM, et al. Enhancing SARC-F: Improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc 2016;17:1136–1141.CrossRefPubMed Barbosa-Silva TG, Menezes AMB, Bielemann, RM, et al. Enhancing SARC-F: Improving sarcopenia screening in the clinical practice. J Am Med Dir Assoc 2016;17:1136–1141.CrossRefPubMed
8.
go back to reference Kemmler W, Sieber C, Freiberger E, et al. The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia. Gerontology 2017;63:411–416CrossRefPubMed Kemmler W, Sieber C, Freiberger E, et al. The SARC-F Questionnaire: Diagnostic Overlap with Established Sarcopenia Definitions in Older German Men with Sarcopenia. Gerontology 2017;63:411–416CrossRefPubMed
9.
go back to reference Charlotte B, Medea L, Stephen B, et al. French translation and validation of the sarcopenia screening tool SARC-F. Eur Geriatr Med 2018;9.1:29–37 Charlotte B, Medea L, Stephen B, et al. French translation and validation of the sarcopenia screening tool SARC-F. Eur Geriatr Med 2018;9.1:29–37
10.
go back to reference Kim S, Kim M, Won CW. Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. J Am Med Dir Assoc 2018;19:40–45.CrossRefPubMed Kim S, Kim M, Won CW. Validation of the Korean version of the SARC-F questionnaire to assess sarcopenia: Korean frailty and aging cohort study. J Am Med Dir Assoc 2018;19:40–45.CrossRefPubMed
12.
go back to reference Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The Index of Adl: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–9.PubMed Katz S, Ford AB, Moskowitz RW, et al. Studies of illness in the aged. The Index of Adl: a standardized measure of biological and psychosocial function. JAMA 1963;185:914–9.PubMed
13.
14.
go back to reference Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. J Ann Med 2001;33:337–43.CrossRef Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. J Ann Med 2001;33:337–43.CrossRef
15.
go back to reference Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:59–65.CrossRef Guigoz Y, Vellas B, Garry PJ. Assessing the nutritional status of the elderly: The Mini Nutritional Assessment as part of the geriatric evaluation. Nutr Rev 1996;54:59–65.CrossRef
16.
go back to reference Cho YC, Alessi CA, Cho M et al. The association between chronic illness and functional change among participants in Comprehensive Geriatric Assessment Program. J Am Geriatr Soc 1998; 46:677–682.CrossRefPubMed Cho YC, Alessi CA, Cho M et al. The association between chronic illness and functional change among participants in Comprehensive Geriatric Assessment Program. J Am Geriatr Soc 1998; 46:677–682.CrossRefPubMed
17.
go back to reference Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423.CrossRefPubMedPubMedCentral Cruz-Jentoft AJ, Baeyens JP, Bauer JM, et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010;39:412–423.CrossRefPubMedPubMedCentral
18.
go back to reference Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates J Gerontol A Biol Sci Med Sci 2014;69:547–558.CrossRefPubMedPubMedCentral Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates J Gerontol A Biol Sci Med Sci 2014;69:547–558.CrossRefPubMedPubMedCentral
19.
go back to reference Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011;12:249–256. Fielding RA, Vellas B, Evans WJ, et al. Sarcopenia: An undiagnosed condition in older adults. Current consensus definition: Prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011;12:249–256.
20.
21.
go back to reference Buatois S, Perret-Guillaume C, Gueguen R, Miget P, et al. A simple clinical scale to stratify risk of recurrent falls in community-dwelling adults aged 65 years and older. Phys Ther 2010;90:550–60.CrossRefPubMed Buatois S, Perret-Guillaume C, Gueguen R, Miget P, et al. A simple clinical scale to stratify risk of recurrent falls in community-dwelling adults aged 65 years and older. Phys Ther 2010;90:550–60.CrossRefPubMed
22.
go back to reference Atsuhiro T, Masayoshi K, Ryosaku K, et al. Age-Related Changes in Physical Function in Community-Dwelling People Aged 50–79 Years. J Phys Ther Sci 2010;22:23–27.CrossRef Atsuhiro T, Masayoshi K, Ryosaku K, et al. Age-Related Changes in Physical Function in Community-Dwelling People Aged 50–79 Years. J Phys Ther Sci 2010;22:23–27.CrossRef
23.
go back to reference Working Group on Functional Outcome Measures for Clinical Trials. Functional outcomes for clinical trials in frail older persons: time to be moving. J Gerontol A Biol Sci Med Sci 2008;63:160–4. Working Group on Functional Outcome Measures for Clinical Trials. Functional outcomes for clinical trials in frail older persons: time to be moving. J Gerontol A Biol Sci Med Sci 2008;63:160–4.
24.
go back to reference Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:85–94CrossRef Guralnik JM, Simonsick EM, Ferrucci L, et al. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol 1994;49:85–94CrossRef
25.
go back to reference Duncan PW, Studenski S, Chandler J, et al. Functional reach: predictive validity in a sample of elderly male veterans. J Gerontol 1992;47:93–98.CrossRef Duncan PW, Studenski S, Chandler J, et al. Functional reach: predictive validity in a sample of elderly male veterans. J Gerontol 1992;47:93–98.CrossRef
26.
go back to reference Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012;16:601–608.CrossRefPubMedPubMedCentral Morley JE, Malmstrom TK, Miller DK. A simple frailty questionnaire (FRAIL) predicts outcomes in middle aged African Americans. J Nutr Health Aging 2012;16:601–608.CrossRefPubMedPubMedCentral
27.
go back to reference Nunnally JC, Bernstein I. Psychometric theory, 3. Ed. New York: McGrawHill Inc, 1994. Nunnally JC, Bernstein I. Psychometric theory, 3. Ed. New York: McGrawHill Inc, 1994.
28.
go back to reference Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc 2014;15:630–634CrossRefPubMed Woo J, Leung J, Morley JE. Validating the SARC-F: a suitable community screening tool for sarcopenia? J Am Med Dir Assoc 2014;15:630–634CrossRefPubMed
29.
go back to reference Yang M, Hu X, Xie, L, et al. Screening Sarcopenia in Community-Dwelling Older Adults: SARC-F vs SARC-F Combined With Calf Circumference (SARC-CalF). J Am Med Dir Assoc 2018;19:277–278.CrossRefPubMed Yang M, Hu X, Xie, L, et al. Screening Sarcopenia in Community-Dwelling Older Adults: SARC-F vs SARC-F Combined With Calf Circumference (SARC-CalF). J Am Med Dir Assoc 2018;19:277–278.CrossRefPubMed
30.
go back to reference Ishiyama D, Yamada M, Makino A, et al. The cut-off point of short physical performance battery score for sarcopenia in older cardiac inpatients. Eur Geriatr Med 2017;8:299–303.CrossRef Ishiyama D, Yamada M, Makino A, et al. The cut-off point of short physical performance battery score for sarcopenia in older cardiac inpatients. Eur Geriatr Med 2017;8:299–303.CrossRef
Metadata
Title
Performance of SARC-F in Regard to Sarcopenia Definitions, Muscle Mass and Functional Measures
Authors
Gülistan Bahat
O. Yilmaz
C. Kiliç
M. M. Oren
M. A. Karan
Publication date
01-10-2018
Publisher
Springer Paris
Published in
The journal of nutrition, health & aging / Issue 8/2018
Print ISSN: 1279-7707
Electronic ISSN: 1760-4788
DOI
https://doi.org/10.1007/s12603-018-1067-8

Other articles of this Issue 8/2018

The journal of nutrition, health & aging 8/2018 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.